226 related articles for article (PubMed ID: 36971796)
1. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
Gigante E; Bouattour M; Bedoya JU; Regnault H; Ziol M; Assenat E; Paradis V; Calderaro J; Ganne-Carrié N; Bouhier-Leporrier K; Amaddeo G; Nault JC
United European Gastroenterol J; 2024 May; 12(4):429-439. PubMed ID: 38059651
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Kim EJ; Yoo C; Kang HJ; Kim KP; Ryu MH; Park SR; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY
Liver Int; 2021 Jun; 41(6):1398-1408. PubMed ID: 33548073
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
Roessler D; Öcal O; Philipp AB; Markwardt D; Munker S; Mayerle J; Jochheim LS; Hammer K; Lange CM; Geier A; Seidensticker M; Reiter FP; De Toni EN; Ben Khaled N
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3065-3073. PubMed ID: 35864269
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma-a European multicenter cohort.
Pomej K; Balcar L; Shmanko K; Welland S; Himmelsbach V; Scheiner B; Mahyera A; Mozayani B; Trauner M; Finkelmeier F; Weinmann A; Vogel A; Pinter M
ESMO Open; 2023 Feb; 8(1):100783. PubMed ID: 36753993
[TBL] [Abstract][Full Text] [Related]
9. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
[TBL] [Abstract][Full Text] [Related]
10. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.
Juloori A; Katipally RR; Lemons JM; Singh AK; Iyer R; Robbins JR; George B; Hall WA; Pitroda SP; Arif F; Fung J; Pillai A; Liao CY; Sharma M; Liauw SL
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):202-213. PubMed ID: 36108891
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.
Yang XG; Sun YY; Li DS; Xu GH; Huang XQ
Front Immunol; 2022; 13():940009. PubMed ID: 35874708
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma.
Villalobos A; Dabbous HH; Little O; Gbolahan OB; Akce M; Lilly MA; Bercu Z; Kokabi N
Curr Oncol; 2023 Nov; 30(12):10100-10110. PubMed ID: 38132368
[TBL] [Abstract][Full Text] [Related]
14. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
Kudo M; Matilla A; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; Tschaika M; Wisniewski T; Sangro B
J Hepatol; 2021 Sep; 75(3):600-609. PubMed ID: 34051329
[TBL] [Abstract][Full Text] [Related]
15. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
[TBL] [Abstract][Full Text] [Related]
16. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
[TBL] [Abstract][Full Text] [Related]
18. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma.
Sucre S; Bullock A; Peters ML
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38697678
[TBL] [Abstract][Full Text] [Related]
20. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.
Gigante E; Hobeika C; Le Bail B; Paradis V; Tougeron D; Lequoy M; Bouattour M; Blanc JF; Ganne-Carrié N; Tran H; Hollande C; Allaire M; Amaddeo G; Regnault H; Vigneron P; Ronot M; Elkrief L; Verset G; Trepo E; Zaanan A; Ziol M; Ningarhari M; Calderaro J; Edeline J; Nault JC
Liver Cancer; 2022 Sep; 11(5):460-473. PubMed ID: 36158591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
